Skip to main
ATNM
ATNM logo

Actinium Pharmaceuticals (ATNM) Stock Forecast & Price Target

Actinium Pharmaceuticals (ATNM) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Actinium Pharmaceuticals Inc. is experiencing a positive outlook driven by its innovative approach to cancer treatment via its antibody-drug constructs, Iomab-B and Actimab-A, which utilize proprietary technology to target cancer cells directly. Recent preclinical data supporting Actimab-A's ability to selectively deplete myeloid-derived suppressor cells (MDSCs) in solid tumors enhances the anticipated efficacy of existing checkpoint inhibitors, thus de-risking ongoing and future clinical investigations. Furthermore, the initiation of a clinical trial under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute signifies strong strategic partnerships that could lead to significant cost savings and support the advancement of Actinium’s product candidates.

Bears say

Actinium Pharmaceuticals Inc. faces potential setbacks due to the risk of failed or inconclusive clinical trials, which could hinder the development of its key product candidates, Iomab-B and Actimab-A. Additionally, the company's reliance on securing adequate funding to progress these drugs through their development pathway poses a significant financial risk. Despite the presence of a substantial unmet medical need for effective therapies in acute myeloid leukemia (AML), these challenges contribute to a negative outlook for the company's stock performance.

Actinium Pharmaceuticals (ATNM) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Actinium Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Actinium Pharmaceuticals (ATNM) Forecast

Analysts have given Actinium Pharmaceuticals (ATNM) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Actinium Pharmaceuticals (ATNM) has a Strong Buy consensus rating as of Jul 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Actinium Pharmaceuticals (ATNM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.